Synapse - Works

Results (39034)

Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience

Meeting Abstract

Saliby, R. M.; Jammihal, T.; Labaki, C.; Xie, W.; Motzer, R. J.; Powles, T.; Rini, B. I.; Albiges, L.; Pal, S. K.; McKay, R. R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Meeting Abstract

Sandhu, S.; Attard, G.; Olmos, D.; Efstathiou, E.; Castro, E.; Rathkopf, D. E.; Smith, M. R.; Roubaud, G.; Small, E. J.; Gomes, A. J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662)

Meeting Abstract

Sacco, J. J.; Orloff, M. M.; Patel, S. P.; Conway, M.; Lim, L. A.; Fog, L. S.; Sia, D.; McKenzie, J.; McKay, D.; O'Day, R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC)

Meeting Abstract

Rugo, H. S.; O'Shaughnessy, J.; Jhaveri, K. L.; Tolaney, S. M.; Cardoso, F.; Bardia, A.; Maheshwari, V. K.; Tripathi, S.; Pathak, P.; Haftchenary, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Meeting Abstract

Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D. E.; Mamtani, R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Neoadjuvant nivolumab in early-stage non-small cell lung cancer (NSCLC): Five-year outcomes

Meeting Abstract

Rosner, S.; Reuss, J. E.; Zahurak, M.; Taube, J. M.; Broderick, S.; Jones, D. R.; Chaft, J. E.; Forde, P. M.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer

Meeting Abstract

Safonov, A. M.; Bandlamudi, C.; Selenica, P.; Marra, A.; Ferraro, E.; Mandelker, D.; Solit, D. B.; Berger, M. F.; Norton, L.; Powell, S. N.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)

Meeting Abstract

Roeker, L. E.; Alencar, A. J.; Murthy, G. S. G.; Hoffmann, M. S.; Pagel, J. M.; Patel, V.; Pauff, J. M.; Zinzani, P. L.; Le Gouill, S.; Mato, A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro)

Meeting Abstract

Rosen, L. S.; Camidge, D. R.; Khalil, D.; Lillie, T.; Carter, J.; Krige, D.; Davies, J.; Miles, D.; Patel, M.; Evilevitch, V.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)

Meeting Abstract

Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save